The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of Frenkel Ran since 2015.
This trader's CIK number is 1623108.
At the time of last reporting, Frenkel Ran was the EVP, Chief Dev. Officer of Karyopharm Therapeutics Inc.. (stock ticker symbol KPTI).
Also see all insider trading activities at Karyopharm Therapeutics Inc..
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2022 | KPTI | 0 | $0 | 6,583 | $72,168 | 0 | $0 |
| 2021 | KPTI | 0 | $0 | 4,933 | $74,568 | 15,325 | $0 |
| 2020 | KPTI | 0 | $0 | 4,949 | $88,513 | 9,675 | $0 |
| 2017 | KPTI | 0 | $0 | 4,958 | $55,757 | 15,000 | $0 |
| 2016 | KPTI | 0 | $0 | 3,309 | $33,285 | 15,000 | $0 |
| 2015 | KPTI | 3,000 | $95,430 | 0 | $0 | 0 | $0 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2022-02-28 | KPTI | Sale | 1,663 | 10.24 | 17,025 |
| 2022-02-17 | KPTI | Sale | 2,929 | 12.12 | 35,508 |
| 2022-02-07 | KPTI | Sale | 1,991 | 9.86 | 19,635 |
| 2021-02-18 | KPTI | Sale | 2,887 | 14.83 | 42,817 |
| 2021-02-11 | KPTI | Sale | 2,046 | 15.52 | 31,751 |
| 2021-02-15 | KPTI | Option Ex | 9,675 | .00 | 0 |
| 2021-02-05 | KPTI | Option Ex | 5,650 | .00 | 0 |
| 2020-05-07 | KPTI | Sale | 1,974 | 20.00 | 39,480 |
| 2020-02-19 | KPTI | Sale | 2,975 | 16.48 | 49,033 |
| 2020-02-15 | KPTI | Option Ex | 9,675 | .00 | 0 |
| 2017-11-07 | KPTI | Sale | 4,958 | 11.25 | 55,757 |
| 2017-11-05 | KPTI | Option Ex | 15,000 | .00 | 0 |
| 2016-11-14 | KPTI | Sale | 3,309 | 10.06 | 33,285 |
| 2016-11-05 | KPTI | Option Ex | 15,000 | .00 | 0 |
| 2015-04-06 | KPTI | Buy | 1,000 | 29.43 | 29,430 |
| 2015-04-07 | KPTI | Buy | 2,000 | 33.00 | 66,000 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Frenkel Ran (EVP, Chief Dev. Officer of Karyopharm Therapeutics Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.